A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Learn more about:
Related Clinical Trial
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Medical Treatment of “High-Risk” Neurofibromas Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Treatment of NF1-related Plexiform Neurofibroma With Trametinib Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Neurofibromatosis Type 1 Brain Tumor Genetic Risk Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I Reliability of Functional Outcome Measures in Neurofibromatosis 1 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Quality of Friendships in Children With Neurofibromatosis Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Interventions for Reading Disabilities in NF1 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Neurobiology and Treatment of Reading Disability in NF-1 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms MicroRNAs in Patients With Neurofibromatosis Type 1 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Stem Cells in NF1 Patients With Tumors of the Central Nervous System Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 Reading Disability in Children With NF1 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients Functional Imaging and Reading Deficit in Children With NF1 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 Effect of Lamotrigine on Cognition in NF1 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia Non-invasive Stimulation in Neurofibromatosis Type 1 Modifying Genes in Neurofibromatosis 1 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 Patient Registry Frameshift Peptides of Children With NF1 Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Brief Title

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Official Title

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

Brief Summary

      The specific aim of this study is to determine whether Lovastatin ™ significantly improves
      visual spatial learning and/or sustained attention in children with NF1.

      Secondary Aims:

      To evaluate the effect of Lovastatin ™ on measures of executive function, behavior and
      quality of life in children with NF1 and cognitive deficits.

      To further evaluate the toxicity and tolerability of Lovastatin ™ in children with NF1 and
      cognitive deficits.

      Hypotheses

      It is hypothesized that Lovastatin ™ will improve the visual spatial memory and/or attention
      deficits in children with NF1. This is based on studies demonstrating that Lovastatin ™ has
      significantly improved impairments in visual spatial memory and attention in the NF1 murine
      model.

      It is further expected that Lovastatin ™ will be safe and well tolerated over a 16-week
      period.
    

Detailed Description

      Study Design

      This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine
      the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of
      children with NF1 aged between 8 and less than 16 years. In addition, the effect of
      Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and
      quality of life will be assessed. Participants will be randomized to 16-weeks of treatment
      with Lovastatin ™ or a matched placebo. It is plausible and ethical to employ a placebo group
      as no standard therapy with established efficacy is being withheld. There is no cross-over in
      this study due to a lack of data concerning the length of possible washout effects. The
      Lovastatin ™ dose will begin at 20 mg once daily/continuous dosing and escalate over a
      two-week period to 40 mg once daily/continuous dosing and continue at this dose for 14 weeks.
      Participants will be carefully monitored for side effects. The safety of Lovastatin ™ will be
      evaluated using laboratory tests, clinical signs and adverse effects, which will be monitored
      at regular intervals over the 16-week period. Primary and secondary outcome measures will be
      administered at baseline, 16 weeks post-treatment and at follow-up, 8 weeks after cessation
      of treatment to determine any carry-over effects. The safety of Lovastatin ™ will also be
      evaluated, with regular monitoring of side-effects during the trial.

      Study Population

      This is a Phase II study involving children with NF1 (aged between 8 years to 15 years 11
      months old at time of enrollment) with evidence of cognitive impairment, defined as having a
      score of at least one standard deviation or more below the population mean on a measure of
      visual spatial learning and/or attention.

      A total of 142 participants with NF1 aged between 8 years and 15 years 11 months will be
      enrolled in the study. The age limits were selected on the basis that Lovastatin ™ has been
      shown to be safe in children aged between 8 and 17 years old. In addition, one of the primary
      outcome measures (attention) only has normative data for up to 15 years 11 months. Therefore,
      the maximum age limit for participants at time of enrolment is 15 years 11 months so that
      normative data can be used to determine whether participants are impaired. The pediatric NF1
      population is an ideal group in which to study the cognitive effects of Lovastatin ™ because
      it represents an opportunity for early pharmacological intervention of cognitive deficits.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Paired Associate Learning (Cambridge Neuropsychological Test Automated Battery).

Secondary Outcome

 Spatial Working Memory (Cambridge Neuropsychological Test Automated Battery)

Condition

Neurofibromatosis Type 1

Intervention

Lovastatin ™

Study Arms / Comparison Groups

 2
Description:  This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

146

Start Date

July 2009

Completion Date

December 2016

Primary Completion Date

May 2014

Eligibility Criteria

        Inclusion Criteria:

          -  Males or females aged between 8 years and 15 years 11 months at time of enrollment who
             meet NIH diagnostic criteria for NF1 (Appendix 1)

          -  Participants must have a full-scale IQ of 70 or above. In cases where there is a
             statistically significant difference between verbal IQ and performance IQ (.05 level
             as determined by Table B3 in the WASI manual), participants will be eligible if at
             least one of these quotients is 70 or above

          -  Participants must have a cognitive impairment defined as having a score of at least
             one standard deviation or more below the population mean on one or more of the primary
             objective outcome measures (i.e., impaired on a measure of visual spatial learning
             and/or sustained attention)

          -  Participants must be medically stable

          -  Participants who are on a stable dose of methylphenidate and/or dextroamphetamines for
             at least one month prior to screening and who will remain on the same dose for the
             duration of the study.

          -  Hepatic function: Participants must have a bilirubin within normal limits and AST and
             ALT ± 2 times the upper limit of normal as determined by the standards at their
             institution

          -  Renal function: Participants must have an age-adjusted normal serum creatinine or a
             creatinine clearance of greater than 70 ml/m/1.73m2

          -  Hematologic function: Participants must have an absolute neutrophil count of greater
             than 1,500, a hemoglobin of greater than 9 gms/dl, and a platelet count of greater
             than 100,000 on study entry

          -  Participants must sign all required documents, including informed assent and HIPAA
             documents

          -  Female participants of childbearing age should not be pregnant, must have a negative
             pregnancy test before initiation of treatment, and take appropriate birth control
             precautions to participate in this study.

        Exclusion Criteria:

          -  Full-scale IQ less than 70; In cases where this is a statistically significant
             difference between performance IQ and verbal IQ (.05 level), patients will be excluded
             if both quotients fall below 70

          -  Individuals that are not cognitively impaired on at least one of the primary objective
             outcome measures

          -  Individuals with insufficient English to complete the assessments

          -  Participants taking psychotropic medication other than methylphenidate and/or
             dextroamphetamines. These patients are eligible if, as clinically indicated, they
             cease medication for at least 30 days prior to screening and remain off these
             medication for the duration of the study

          -  Participants with intracranial pathology such as epilepsy, diagnosed head injury,
             hydrocephalus or progressive intracranial tumors (children with asymptomatic or static
             lesions will be eligible)

          -  Participants who are pregnant or breastfeeding; Participants who have received any
             investigational drug, other than sirolimus, within 30 days of initiation of study

          -  Participants who have recently taken Lovastatin. These participants will be eligible
             after a washout period of at least three months.

          -  Participants with significant hepatic, renal or hematologic function as previously
             defined

          -  Participants with a history of neuromuscular disease, excluding hypotonias thought to
             be associated with NF1

          -  Participants with a clinically significant unrelated illness, which in the judgment of
             the principal or associate investigator, would compromise the participant's ability to
             tolerate the medication or potentially interfere with the participant's ability to
             participate in the required testing

          -  Low cholesterol (lower limit of a total cholesterol of 90mg/dl)

          -  Participants who have recently taken sirolimus within three months of enrollment.
             These participants will be eligible after a washout period of at least three months.
      

Gender

All

Ages

8 Years - 15 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Kathryn North, MD, , 

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT00853580

Organization ID

X080929007

Secondary IDs

DOD: W81XWH-05-1 0615

Responsible Party

Principal Investigator

Study Sponsor

University of Alabama at Birmingham

Collaborators

 Boston Children's Hospital

Study Sponsor

Kathryn North, MD, Principal Investigator, University of Sydney - Westmead


Verification Date

March 2018